NeoTX commences dosing in Phase Ib trial of naptumomab

The Phase Ib trial will investigate naptumomab plus Imfinzi for treating advanced or metastatic solid tumours. Credit: Dr. Cecil Fox, National Cancer Institute, National Institutes of Health.



  • NeoTX commences dosing in Phase Ib trial of naptumomab